Clovis Oncology Announces Third Quarter 2018 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Clovis Oncology (CLVS) PT Slashed 74% to $19 at RBC Capital
October 31, 2018 7:14 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Clovis Oncology (NASDAQ: CLVS) to $19.00 (from $73.00) while maintaining a Outperform rating.
MacKay notes Rubraca's PARPi competition impact sets in.
... MoreClovis Oncology (CLVS) Misses Q3 EPS by 11c
October 30, 2018 4:25 PM EDTClovis Oncology (NASDAQ: CLVS) reported Q3 EPS of ($1.71), $0.11 worse than the analyst estimate of ($1.60). Revenue for the quarter came in at $22.76 million versus the consensus estimate of $30.11 million.
As discussed last quarter, growth remains challenging in the second-line maintenance ovarian cancer setting,... More
